Sodium glucose cotransporter 2 inhibitor-induced ketoacidosis is unlikely in patients without diabetes.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Australasian Medical Publishing Co Country of Publication: Australia NLM ID: 0400714 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1326-5377 (Electronic) Linking ISSN: 0025729X NLM ISO Abbreviation: Med J Aust Subsets: MEDLINE
    • Publication Information:
      Publication: : Pyrmont, NSW : Australasian Medical Publishing Co.
      Original Publication: Sydney : Australasian Medical Pub. Co.
    • Subject Terms:
      Sodium-Glucose Transporter 2 Inhibitors*/adverse effects ; Diabetes Mellitus, Type 2*/drug therapy ; Ketosis*/chemically induced ; Diabetic Ketoacidosis*/chemically induced ; Diabetic Ketoacidosis*/diagnosis; Humans ; Hypoglycemic Agents/adverse effects
    • References:
      Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128.
      Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347-357.
      McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381: 1995-2008.
      Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383: 1413-1424.
      Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021; 385: 1451-1461.
      Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022; 387: 1089-1098.
      EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023; 388: 117-127.
      Handelsman Y, Henry RR, Bloomgarden ZT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract 2016; 22: 753-762.
      Hamblin PS, Wong R, Ekinci EI, et al. Capillary ketone concentrations at the time of colonoscopy: a cross-sectional study with implications for SGLT2 inhibitor-treated type 2 diabetes. Diabetes Care 2021; 44: e124-e126.
      Blau JE, Tella SH, Taylor SI, Rother KI. Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data. Diabetes Metab Res Rev 2017; 33. https://doi.org/10.1002/dmrr.2924.
      Ogurtsova K, Guariguata L, Barengo NC, et al. IDF Diabetes Atlas: global estimates of undiagnosed diabetes in adults for 2021. Diabetes Res Clin Pract 2022; 183: 109118.
    • Contributed Indexing:
      Keywords: Diabetes mellitus, type 2; Kidney diseases; Pharmacovigilance
    • Accession Number:
      0 (Sodium-Glucose Transporter 2 Inhibitors)
      0 (Hypoglycemic Agents)
    • Publication Date:
      Date Created: 20230807 Date Completed: 20231003 Latest Revision: 20231004
    • Publication Date:
      20231004
    • Accession Number:
      10.5694/mja2.52067
    • Accession Number:
      37549922